Express Scripts kicks another batch of meds off its preferred formulary

Vocal pharma-pricing critic Express Scripts ($ESRX) added almost 20 products to its list of excluded meds for 2016. With 80 drugs now ineligible for routine reimbursement, the pharmacy benefits manager says it has excluded about $1.3 billion worth of costs. The new National Preferred Formulary can apply to up to 25 million members. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.